Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Gene Expression Model Predicts PFS in Follicular Lymphoma

February 28th 2018

A “robust” 23-gene expression-based model successfully predicted progression-free survival for patients with follicular lymphoma enrolled in the phase III randomized PRIMA trial.

Dr. Locke Discusses the Impact of the ZUMA-1 Trial in NHL

February 14th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses the impact of the ZUMA-1 trial for patients with non-Hodgkin Lymphoma (NHL).

Dr. Locke Discusses Long-Term Follow-Up of ZUMA-1 Trial for NHL

February 7th 2018

Frederick Locke, MD, a medical oncologist in the Department of Blood and Marrow Transplant at Moffitt Cancer Center, and an assistant professor of Oncology at the University of South Florida, discusses long-term follow-up results of the ZUMA-1 trial for patients with non-Hodgkin lymphoma (NHL).

Dr. Skarbnik on Impact of Checkpoint Inhibition Following ASCT

January 30th 2018

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, department of Lymphoma, John Theurer Cancer Center, discusses the preliminary safety and efficacy data for checkpoint inhibition with ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplantation in high-risk hematologic malignancies.

Liso-Cel Highly Active in Relapsed/Refractory DLBCL

January 30th 2018

David G. Maloney, MD, PhD, discusses the promise of lisocabtagene maraleucel in patients with diffuse large B-cell lymphoma.

Advances and Research Needs in Lymphoma

January 26th 2018

Investigating CAR T-Cell Therapy in Lymphoma

January 26th 2018

Approval of Acalabrutinib in Mantle Cell Lymphoma

January 26th 2018

Duration of Rituximab Maintenance in FL

January 26th 2018

Long-Term Data With Copanlisib in Follicular Lymphoma

January 26th 2018

Follicular Lymphoma: Obinutuzumab and Chemotherapy

January 26th 2018

MAVORIC Trial in Cutaneous T-Cell Lymphoma

January 26th 2018

Primary Cutaneous T-cell Lymphoma: ALCANZA Trial

January 26th 2018

Role of Novel Therapies in Hodgkin Lymphoma

January 26th 2018

Novel Combinations in Relapsed Hodgkin Lymphoma

January 26th 2018

Hodgkin Lymphoma: Addressing the Elderly Population

January 26th 2018

Hodgkin Lymphoma: Important Findings from CheckMate 205

January 26th 2018

Hodgkin Lymphoma: Using Brentuximab Vedotin Frontline

January 26th 2018

ECHELON-1 Trial: Significance in Hodgkin Lymphoma

January 26th 2018

Novel Antibody Tested in First-Line DLBCL Therapy

January 25th 2018

Investigators are studying the value of polatuzumab vedotin in patients with intermediate- or high-risk diffuse large B-cell lymphoma.